Ocular Therapeutix™ to Present at Two Investor Conferences in September
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on improving vision through innovative therapies, has announced its participation in two upcoming investor conferences in September 2024. The company will be present at:
1. The Baird 2024 Global Healthcare Conference on Tuesday, September 10, with a fireside chat scheduled for 12:50 PM ET in New York, NY.
2. The H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, featuring a fireside chat at 8:30 AM ET, also in New York, NY.
Investors can access a live webcast of the H.C. Wainwright fireside chat through the Investors section of Ocular Therapeutix's website at investors.ocutx.com.
Ocular Therapeutix (NASDAQ: OCUL), un'azienda biofarmaceutica focalizzata sul miglioramento della visione attraverso terapie innovative, ha annunciato la propria partecipazione a due prossimi conferenze per investitori che si terranno a settembre 2024. L'azienda sarà presente a:
1. La Baird 2024 Global Healthcare Conference martedì 10 settembre, con una chiacchierata informale programmata per le 12:50 PM ET a New York, NY.
2. La H.C. Wainwright 26th Annual Global Investment Conference mercoledì 11 settembre, con una chiacchierata informale alle 8:30 AM ET, sempre a New York, NY.
Gli investitori possono accedere a una trasmissione in diretta della chiacchierata informale di H.C. Wainwright attraverso la sezione Investitori del sito web di Ocular Therapeutix all'indirizzo investors.ocutx.com.
Ocular Therapeutix (NASDAQ: OCUL), una compañía biofarmacéutica enfocada en mejorar la visión a través de terapias innovadoras, ha anunciado su participación en dos conferencias de inversionistas que se llevarán a cabo en septiembre de 2024. La compañía estará presente en:
1. La Baird 2024 Global Healthcare Conference el martes 10 de septiembre, con una charla informal programada para las 12:50 PM ET en Nueva York, NY.
2. La H.C. Wainwright 26th Annual Global Investment Conference el miércoles 11 de septiembre, que contará con una charla informal a las 8:30 AM ET, también en Nueva York, NY.
Los inversionistas pueden acceder a una transmisión en vivo de la charla informal de H.C. Wainwright a través de la sección de Inversionistas del sitio web de Ocular Therapeutix en investors.ocutx.com.
Ocular Therapeutix (NASDAQ: OCUL)는 혁신적인 치료법을 통해 시력을 개선하는 데 집중하는 생명공학 회사로, 2024년 9월의 두 가지 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 다음 회의에 참석할 예정입니다:
1. Baird 2024 Global Healthcare Conference가 9월 10일 화요일에 열리며, 오후 12:50 ET에 뉴욕에서 간담회가 예정되어 있습니다.
2. H.C. Wainwright 제26회 연례 글로벌 투자 회의가 9월 11일 수요일에 열리며, 오전 8:30 ET에 역시 뉴욕에서 간담회가 진행될 예정입니다.
투자자들은 Ocular Therapeutix 웹사이트의 투자자 섹션에서 H.C. Wainwright 간담회의 라이브 웹캐스트에 접속할 수 있습니다: investors.ocutx.com.
Ocular Therapeutix (NASDAQ: OCUL), une société bio-pharmaceutique axée sur l'amélioration de la vision grâce à des thérapies innovantes, a annoncé sa participation à deux prochaines conférences d'investisseurs en septembre 2024. L'entreprise sera présente à :
1. La Baird 2024 Global Healthcare Conference le mardi 10 septembre, avec une discussion informelle prévue à 12h50 HE à New York, NY.
2. La H.C. Wainwright 26th Annual Global Investment Conference le mercredi 11 septembre, avec une discussion informelle à 8h30 HE, également à New York, NY.
Les investisseurs peuvent accéder à un webcast en direct de la discussion informelle de H.C. Wainwright via la section Investisseurs du site web d'Ocular Therapeutix à l'adresse investors.ocutx.com.
Ocular Therapeutix (NASDAQ: OCUL), ein biopharmazeutisches Unternehmen, das sich auf die Verbesserung des Sehens durch innovative Therapien konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird vertreten sein bei:
1. Der Baird 2024 Global Healthcare Conference am Dienstag, den 10. September, mit einem informellen Gespräch, das für 12:50 Uhr ET in New York, NY angesetzt ist.
2. Der H.C. Wainwright 26th Annual Global Investment Conference am Mittwoch, den 11. September, mit einem informellen Gespräch um 8:30 Uhr ET, ebenfalls in New York, NY.
Investoren können über den Investorenbereich der Website von Ocular Therapeutix unter investors.ocutx.com auf einen Live-Stream des informellen Gespächs von H.C. Wainwright zugreifen.
- None.
- None.
BEDFORD, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in two investor conferences in September:
Baird 2024 Global Healthcare Conference
Fireside Chat Date: Tuesday, September 10, 2024
Presentation Time: 12:50 PM ET
Location: New York, NY
H.C. Wainwright 26th Annual Global Investment Conference
Fireside Chat Date: Wednesday, September 11, 2024
Fireside Chat Time: 8:30 AM ET
Location: New York, NY
A live webcast of the H.C. Wainwright fireside chat can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What investor conferences will Ocular Therapeutix (OCUL) attend in September 2024?
When is Ocular Therapeutix's (OCUL) fireside chat at the Baird 2024 Global Healthcare Conference?
Can investors watch Ocular Therapeutix's (OCUL) presentation at the H.C. Wainwright conference?
Where will the September 2024 investor conferences featuring Ocular Therapeutix (OCUL) be held?
